262 results
8-K
EX-99.1
ALNY
Alnylam Pharmaceuticals Inc
11 Jan 21
Alnylam Launches “Alnylam P5x25” Strategy for Planned Transition to a Top Five Biotech in Market Capitalization Over Next Five Years
8:37am
)
617-551-8276
Alnylam Launches “Alnylam P5x25” Strategy for Planned Transition to a Top Five Biotech in Market Capitalization Over Next Five Years …
– New 5-Year Strategy Represents Alnylam’s Commitment to Delivering Transformative Rare and Prevalent Disease Medicines for Patients Around the World
8-K
EX-99.2
ALNY
Alnylam Pharmaceuticals Inc
28 Oct 21
Alnylam Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity
8:11am
,” said Michael Bonney, Alnylam Executive Chair. “As we prepare for Alnylam’s continued leadership and execution on our P5x25 business strategy, we … industry, driving strategy and innovation, bringing transformative medicines to patients, and building successful businesses in the US, Europe and globally
8-K
EX-99.1
ALNY
Alnylam Pharmaceuticals Inc
20 Jan 12
Results of Operations and Financial Condition
12:00am
Opportunities in “Alnylam 5x15™” Product Strategy
Cambridge, Mass., January 19, 2012 –Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi … development plans. These include a previously announced company focus on its “Alnylam 5x15” RNAi therapeutic product strategy with ALN-TTR for the treatment
8-K
EX-99.1
ALNY
Alnylam Pharmaceuticals Inc
7 Jan 13
Results of Operations and Financial Condition
12:00am
efforts with our ‘Alnylam 5x15’ product strategy focused on genetically defined targets for diseases with limited treatment options for patients … shareholders.”
“Alnylam 5x15” Product Strategy Goals
Advance ALN-TTR02 into Phase III Pivotal Trial in Familial Amyloidotic Polyneuropathy (FAP).ALN-TTR02
8-K
EX-99.1
ALNY
Alnylam Pharmaceuticals Inc
2 May 11
Alnylam Pharmaceuticals Reports First Quarter 2011 Financial Results
12:00am
Exhibit 99.1
Alnylam Pharmaceuticals Reports First Quarter 2011 Financial Results
– Launched ‘Alnylam 5x15™’ Product Strategy Focused … 5x15’ product strategy and advanced our core pipeline programs, together with our partner-based programs, in clinical and pre-clinical development
8-K
EX-99.1
tepzag np2fok5
17 Feb 11
Alnylam Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
12:00am
8-K
EX-99.1
b4neyz
6 May 13
Alnylam Pharmaceuticals Reports First Quarter 2013 Financial Results
12:00am
8-K
EX-99.1
60t4ula
4 Jan 22
Alnylam Announces Promotion of Dr. Akshay Vaishnaw to President
4:16pm
8-K
EX-99.1
hbmgwh v52m
7 Feb 13
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results
12:00am
8-K
EX-99.1
zpq9x7pijzvi vgx
3 May 12
Alnylam Pharmaceuticals Reports First Quarter 2012 Financial Results
12:00am
8-K
EX-99.1
sxlhgnr
1 Nov 11
Alnylam Pharmaceuticals Reports Third Quarter 2011 Financial Results
12:00am
CORRESP
8tz7n5wcr 3p7yiucp
24 Feb 09
Correspondence with SEC
12:00am
8-K
EX-99.1
erdv 7yt0f9ho6ht
10 Jan 22
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Revenues and Provides Additional Updates
7:01am
8-K
EX-99.1
jgmkq1
9 Jan 12
Results of Operations and Financial Condition
12:00am
8-K
EX-99.1
baqz5
5 Apr 22
Alnylam Announces Retirement of Steven Paul, M.D. from Board of Directors
4:16pm
8-K
EX-99.1
35lhr 1gn
9 Feb 12
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results
12:00am
8-K
EX-99.1
xwphoqer l3i
8 Aug 13
Alnylam Pharmaceuticals Reports Second Quarter 2013 Financial Results
12:00am
8-K
EX-99.1
3w1k29hb1yxnmij4njc
26 Jul 23
Entry into a Material Definitive Agreement
5:15pm
8-K
EX-99.1
n9t526jp
5 Nov 12
Alnylam Pharmaceuticals Reports Third Quarter 2012 Financial Results
12:00am
8-K
EX-99.1
dcmztflm4l315lh 0xe7
13 Jan 14
Alnylam Acquires Investigational RNAi Therapeutic Assets from Merck
12:00am